Viemed Healthcare Announces New 2026 Share Repurchase Program: What Investors Need to Know
Key Highlights from the Announcement
- Share Repurchase Authorization: Viemed Healthcare, Inc. (NASDAQ: VMD) has announced that its Board of Directors has approved a new share repurchase program, effective through March 2027. Under this program, the company may repurchase up to 1,930,131 common shares—representing approximately 5% of Viemed’s total issued and outstanding shares as of March 4, 2026.
- Repurchase Mechanism and Compliance: The buyback will be executed via open market purchases, block trades, or other methods permissible under Canadian and U.S. securities laws, specifically adhering to Rule 10b-18 under the U.S. Securities Exchange Act of 1934. Daily purchases (excluding block trades) are capped at 25% of the average daily trading volume over the preceding four weeks to ensure compliance with regulatory requirements.
- Fourth Consecutive Repurchase Program: This marks the fourth share repurchase program in Viemed’s history. In the three previous programs, the company returned approximately \$26.3 million to shareholders by repurchasing about 4.5 million shares.
- Financial Position and Capital Allocation: CEO Casey Hoyt emphasized Viemed’s strong financial health, including record revenue and Adjusted EBITDA in 2025, more than doubling free cash flow year-over-year, and ending the year with virtually no net debt. Viemed finished 2025 with \$13.5 million in cash and significant credit facility availability, supporting both the buyback and ongoing investments in organic growth and selective acquisitions.
- Share Cancellation: All repurchased shares will be cancelled, which will reduce the number of shares outstanding and could enhance shareholder value.
Details and Potential Share Price Impact
The initiation of a new share repurchase program can be a significant and price-sensitive event for shareholders, as it indicates management’s confidence in the company’s financial strength and future prospects. Share buybacks reduce the number of shares outstanding, which may increase earnings per share (EPS) and potentially support the share price. The program’s scale—up to 5% of the company’s outstanding shares—demonstrates a robust commitment to returning capital to shareholders.
The company’s history of completing three prior buyback programs with \$26.3 million returned to shareholders, combined with a strong balance sheet, positions Viemed as a disciplined capital allocator. The flexibility to pause or discontinue the program at any time remains, subject to compliance with applicable laws.
Shareholders should note that the price paid for repurchased shares will be at prevailing market prices plus brokerage fees, ensuring market-based valuation for the buybacks.
Company Overview and Strategic Focus
Viemed Healthcare is a U.S.-based provider of home medical equipment and post-acute healthcare services, specializing in respiratory, chronic care, and women’s health. The company’s care model leverages a combination of high-touch clinical support and technology-enabled services, including therapy, education, and counseling, delivered directly in patients’ homes.
Forward-Looking Statements and Risks
The company cautions that the share buyback program, including the amount and timing of repurchases, the sources of funding, and the anticipated benefits to shareholders, are subject to risks and uncertainties. These include market and economic conditions, capital availability, regulatory changes, and other factors beyond Viemed’s control. The company’s forward-looking statements reflect current expectations but are inherently uncertain.
Investors are advised to review Viemed’s filings with the SEC and Canadian securities regulators for a comprehensive discussion of risk factors.
Contact Information
- Investor Relations: [email protected]
- Trae Fitzgerald, Chief Financial Officer: (337) 504-3802
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. All forward-looking statements are subject to risks and uncertainties as outlined in Viemed Healthcare’s official filings.
View VIEMED HEALTHCARE, INC. Historical chart here
